ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnesium Treatment in Hypoparathyroidism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00824226
Recruitment Status : Completed
First Posted : January 16, 2009
Last Update Posted : August 29, 2011
Sponsor:
Information provided by (Responsible Party):
Vallo Volke, University of Tartu

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Condition or disease Intervention/treatment Phase
Hypoparathyroidism Dietary Supplement: magnesium Not Applicable

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients
Study Start Date : January 2009
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium
Drug Information available for: Magnesium
U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
    Dietary Supplement: magnesium
    magnesium 350 mg tablets once a day for 3 weeks

Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Calcium level at the end of magnesium treatment compared to pretreatment level [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Calcium level after stopping treatment compared to the level at the end of magnesium treatment [ Time Frame: 2 weeks ]

Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • primary or secondary hypoparathyroidism
  • treatment with calcium plus vitamin D analogue
  • ionized calcium 1,0-1,29 mmol/L
  • magnesium level 0,7-1,05 mmol/L
  • TSH 0.1- 10 imU/L

Exclusion Criteria:

  • any other disease known to influence plasma Ca level
  • pregnancy
  • creatinine > 150 microM/L
  • patient has used supplementary magnesium within 2 previous months
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00824226


Locations
Estonia
Tartu University Hospital
Tartu, Estonia, 50406
Sponsors and Collaborators
University of Tartu
Investigators
Principal Investigator: Vallo Volke, MD, PhD University of Tartu, Institute of Physiology
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Vallo Volke, Dr., University of Tartu
ClinicalTrials.gov Identifier: NCT00824226     History of Changes
Other Study ID Numbers: UT296
First Posted: January 16, 2009    Key Record Dates
Last Update Posted: August 29, 2011
Last Verified: August 2011

Keywords provided by Vallo Volke, University of Tartu:
primary hypoparathyroidism
secondary hypoparathyroidism
magnesium

Additional relevant MeSH terms:
Hypoparathyroidism
Parathyroid Diseases
Endocrine System Diseases